

Shingo Kano

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5566298/shingo-kano-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

16
papers

44
citations

5
h-index

5
g-index

20
ext. papers

58
ext. citations

4
avg, IF

2.12
L-index

#	Paper	IF	Citations
16	Integrated Analytical Framework for the Development of Artificial Intelligence-Based Medical Devices. <i>Therapeutic Innovation and Regulatory Science</i> , 2021 , 55, 853-865	1.2	0
15	Comparative analysis of correlations of research and development indicators for rare diseases among Japan, the US, and Europe. <i>Scientometrics</i> , 2019 , 120, 361-374	3	
14	An enforced loop-out knowledge flow facilitates industry competition: Learning from the pharmaceutical and genetically modified seed industries. <i>Technovation</i> , 2019 , 79, 11-24	7.9	1
13	Technology Forecasting for Medical Devices Guidance Formulation: A Case Study in Japan. <i>Therapeutic Innovation and Regulatory Science</i> , 2019 , 53, 481-489	1.2	1
12	Patent term extension systems differentiate Japanese and US drug lifecycle management. <i>Drug Discovery Today</i> , 2016 , 21, 111-117	8.8	6
11	Mapping university receptor patents based on claim-embodiment quantitative analysis: A study of 31 cases from the University of Tokyo. <i>World Patent Information</i> , 2016 , 46, 49-55	1.4	1
10	Quantitative Analysis of the Role of Patents and Drug Approvals in Drug Lifecycle Management in Japan. <i>Pharmaceutical Medicine</i> , 2016 , 30, 157-164	2.3	
9	Mapping lifecycle management activities for blockbuster drugs in Japan based on drug approvals and patent term extensions. <i>Drug Discovery Today</i> , 2016 , 21, 306-14	8.8	2
8	Comparison of international guidelines for regenerative medicine: Knee cartilage repair and replacement using human-derived cells and tissues. <i>Biologicals</i> , 2016 , 44, 267-270	1.8	2
7	Strategic balance of drug lifecycle management options differs between domestic and foreign companies in Japan. <i>Expert Opinion on Therapeutic Patents</i> , 2016 , 26, 497-503	6.8	2
6	Research and drug development activities in rare diseases: differences between Japan and Europe regarding influence of prevalence. <i>Drug Discovery Today</i> , 2016 , 21, 1681-1689	8.8	6
5	Comparison of examiners' forward citations in the United States and Japan with pairs of equivalent patent applications. <i>Scientometrics</i> , 2015 , 102, 1189-1205	3	5
4	A new look at the corporate capability of personalized medicine development in the pharmaceutical industry. <i>R and D Management</i> , 2015 , 45, 94-103	4.1	3
3	Validating the usefulness of examiners' forward citations from the viewpoint of applicants' self-selection during the patent application procedure. <i>Scientometrics</i> , 2014 , 99, 895-909	3	6
2	Effects of new formulation strategy on life cycle management in the US pharmaceutical industry. <i>Journal of Generic Medicines</i> , 2013 , 10, 172-179	0.2	6
1	Definition of the Device Lag and Its Measurement. <i>Iryou Kikigaku (the Japanese Journal of Medical Instrumentation)</i> , 2009 , 79, 273-285	0	2